目的地心室辅助装置:为高级心力衰竭治疗新批准的疗法提供单中心体验
Matanyahu Rubinstein1, Steven Lim1, Janelle McLean1
1Department of Cardiology Alfred Health, Melbourne, Vic, Australia.
Heart, lung & circulation
|March 11, 2026
概括
目的地治疗 (DT) 腹腔辅助装置 (VAD) 植入为澳大利亚的晚期心力衰竭提供了可行的治疗方法. 这种方法显著改善了无法移植的患者的生存率和生活质量.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭管理的管理
背景情况:
- 心室辅助装置 (VAD) 目的地疗法 (DT) 是澳大利亚针对晚期心力衰竭的新型预先治疗方法.
- 它为不适合心脏移植的患者提供了一个选择.
研究的目的:
- 调查与VAD植入相关的死亡率和发病率,以研究晚期心力衰竭.
- 为了确定DT在澳大利亚医疗保健环境中的有效性.
主要方法:
- 在单一中心对2012-2024年VAD接收者的回顾性分析.
- 收集的数据包括患者和VAD特征,血液动力学测量,生活质量得分和生存结果.
主要成果:
- 18名患者接受了VAD,机械辅助循环支持的机构间注册表中位数为2.
- 出院后的中位生存期为5.9年,心力衰竭症状,生活质量得分,步行6分钟的距离和血液动力学参数显著改善.
- 移植资格不合格是由于各种生物心理社会因素.
结论:
- 目的地治疗VAD是澳大利亚先进心力衰竭的移植不合格患者的可行选择.
- VAD DT与生存和生活质量的显著改善有关.
- 未来的研究应该旨在优化远程监测和患者选择,以获得更好的长期结果.
相关概念视频
Heart Failure VI: Adjunct Therapies
496
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
496
Cardiomyopathy V: Interprofessional Care
571
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
571
Cardiomyopathy II: Dilated Cardiomyopathy
700
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
700
Heart Failure V: Medical Management
455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Heart Failure IV: Classification and Diagnostic Evaluation
510
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
510
Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K


